J. Mark Jackson, MD, FAAD
Dr. Jackson is a Clinical Professor of Medicine (Dermatology) at the University of Louisville. Dr. Jackson is active in the dermatology residency program and spends time teaching dermatology residents and medical students. He is also involved in clinical investigational research, as well as in clinical practice. Dr. Jackson has authored many chapters and articles in peer reviewed publications and has lectured throughout the country on topics involving acne, lupus, psoriasis, eczema, systemic therapies for dermatologic diseases and advanced dermatologic disorders. He sees patients primarily at the Louisville office, but also staffs the dermatology clinic at the University of Louisville. Dr. Jackson also serves as an investigator and consultant for pharmaceutical companies in research and drug development.
- Education
-
Undergraduate Degree:
Baylor University – Waco, TXMedical School:
Texas A&M College of Medicine – Bryan, TXInternal Medicine Residency:
Texas A&M College of Medicine – Bryan, TXDermatology Residency:
University of Louisville – Louisville, KY - Certificates
- American Board of Dermatology
- Professional Memberships
- Dermatology Foundation Leaders Society
Medical Dermatology Society
American Academy of Dermatology
American Board of Dermatology
American Acne and Rosacea Society
American Medical Association
Kentucky Dermatological Association
Kentucky Medical Association
Greater Louisville Medical Society
North American Rheumatologic Dermatology Society
Jefferson County Medical Society - Achievements
- Voted Best Dermatologist Louisville Magazine
Upjohn Achievement Award for Virtues Most Admired in a Physician
Department of Internal Medicine Award for Excellence
Golden Apple Award for Outstanding Resident Teacher
Roche Overall Award for Clinical Research, Resident/Intern Division
American Academy of Family Physicians Award for Research
- Publications
Jackson JM, Fowler JF, Callen JP, Lorenz DJ; Mycophenolate mofetil for the treatment An open-label study. J Drugs Dermatol 2010;9:356-62.
Fowler J, Jackson, J, Jarrat M, et al: Once Daily brimonidine tartrate gel 0.5% is a moderate to severe facial erythema of rosacea: results of two randomized, multi-centre, vehicle controlled studies. Br J Dermatol 2012:166:633-41.
Fowler JF, Jackson JM, Steinhoff M, et al: Topical brimonidine tartrate gel is safe and treatment of moderate to severe facial erythema of rosacea. JDrugsDermatol, June 2013.
*Age Restriction
For patients scheduling who are under 18 years of age (19 in Alabama) please make sure you have permission from your parent or legal guardian to schedule this appointment. Your parent or legal guardian must accompany you on your initial visit and on certain subsequent visits to provide appropriate informed consent.